Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

Seminar: Naitee Ting

Statistics Seminar
May 2, 2002
All Day
209 W. Eighteenth Ave. (EA), Room 170

Title

Design of dose response clinical trials

Speaker

Dr. Naitee Ting, Pfizer Global Research & Development

Abstract

In the process of drug discovery and drug development, understanding the dose response relationship is one of the most challenging tasks. It is also critical to identify the right range of doses in early stages of clinical development so that Phase III trials can be designed to confirm these doses. This presentation discusses some of the considerations in designing dose response clinical studies.